(Q79447113)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

title

Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Joaquin Barnoya

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Vladimiro L Vida

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Guillermo Gaitan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Aldo R Castañeda

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

22 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

published in

Cardiology in the Young

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

72-77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Cost of nitric oxide is exorbitant

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Pulmonary arterial hypertension: the race for the most effective treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Advances in the treatment of secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Sildenafil for pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Lung transplantation for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Emerging medical therapies for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Inhaled iloprost in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Treatment of pulmonary arterial hypertension: a preliminary decision analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Oral sildenafil reduces pulmonary hypertension after cardiac surgery

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951106001193

7 January 2021

10.1017/S1047951106001193

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17184573%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference